Loading stock data…
INFU
$10.37+0.24 (+2.37%)
Market ClosedLast close May 1
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
InfuSystem Holdings, Inc. in the Healthcare sector is trading at $10.37. The stock is currently near its 52-week high of $11.04, remaining 13.3% above its 200-day moving average. Technical signals show neutral RSI of 59 and bearish MACD signal, explaining why INFU maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 59) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$10.37
Potential Downside
46.1%
Whystock Fair Value$5.59
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada. It operates through two segments: Patient Services and Device Solutions. The company supplies electronic a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$210.44M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
33.58
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.55
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
0.52%
Volume
Today's trading volume
122,678
Recent News
InfuSystems Holdings Inc (INFU) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...
InfuSystems Holdings Inc (INFU) reports a robust 7% revenue increase and significant debt reduction, while navigating challenges in contract restructuring and cost pressures.
InfuSystem Holdings, Inc. Q4 2025 Earnings Call Summary
Moby summary of InfuSystem Holdings, Inc.'s Q4 2025 earnings call
InfuSystems Holdings, Inc. (INFU) Q4 Earnings Beat Estimates
InfuSystems Holdings (INFU) delivered earnings and revenue surprises of +53.85% and -0.74%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
ICU Medical (ICUI) Q4 Earnings and Revenues Surpass Estimates
ICU Medical (ICUI) delivered earnings and revenue surprises of +13.52% and +1.32%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Prestige Consumer Healthcare (PBH) Q3 Earnings Lag Estimates
Prestige Consumer Healthcare (PBH) delivered earnings and revenue surprises of -1.30% and +0.48%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?